1. Cohort profile: Copenhagen Hospital Biobank - Cardiovascular Disease Cohort (CHB-CVDC): Construction of a large-scale genetic cohort to facilitate a better understanding of heart diseases
- Author
-
Ina H Laursen, Karina Banasik, Amalie D Haue, Oscar Petersen, Peter C Holm, David Westergaard, Henning Bundgaard, Søren Brunak, Ruth Frikke-Schmidt, Hilma Holm, Erik Sørensen, Lise W Thørner, Margit A H Larsen, Michael Schwinn, Lars Køber, Christian Torp-Pedersen, Sisse R Ostrowski, Christian Erikstrup, Mette Nyegaard, Hreinn Stefánsson, Arnaldur Gylfason, Florian Zink, G Bragi Walters, Asmundur Oddsson, Guðmar Þorleifsson, Gisli Másson, Unnur Thorsteinsdottir, Daniel Gudbjartsson, Ole B Pedersen, Kári Stefánsson, and Henrik Ullum
- Subjects
Cohort Studies ,Heart Diseases ,Cardiovascular Diseases ,cardiology ,Humans ,Genetics and Genomics ,epidemiology ,genetics ,General Medicine ,Hospitals ,Biological Specimen Banks - Abstract
PurposeThe aim of Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC) is to establish a cohort that can accelerate our understanding of CVD initiation and progression by jointly studying genetics, diagnoses, treatments and risk factors.ParticipantsThe CHB-CVDC is a large genomic cohort of patients with CVD. CHB-CVDC currently includes 96 308 patients. The cohort is part of CHB initiated in 2009 in the Capital Region of Denmark. CHB is continuously growing with ~40 000 samples/year. Patients in CHB were included in CHB-CVDC if they were above 18 years of age and assigned at least one cardiovascular diagnosis. Additionally, up-to 110 000 blood donors can be analysed jointly with CHB-CVDC. Linkage with the Danish National Health Registries, Electronic Patient Records, and Clinical Quality Databases allow up-to 41 years of medical history. All individuals are genotyped using the Infinium Global Screening Array from Illumina and imputed using a reference panel consisting of whole-genome sequence data from 8429 Danes along with 7146 samples from North-Western Europe. Currently, 39 539 of the patients are deceased.Findings to dateHere, we demonstrate the utility of the cohort by showing concordant effects between known variants and selected CVDs, that is, >93% concordance for coronary artery disease, atrial fibrillation, heart failure and cholesterol measurements and 85% concordance for hypertension. Furthermore, we evaluated multiple study designs and the validity of using Danish blood donors as part of CHB-CVDC. Lastly, CHB-CVDC has already made major contributions to studies of sick sinus syndrome and the role of phytosterols in development of atherosclerosis.Future plansIn addition to genetics, electronic patient records, national socioeconomic and health registries extensively characterise each patient in CHB-CVDC and provides a promising framework for improved understanding of risk and protective variants. We aim to include other measurable biomarkers for example, proteins in CHB-CVDC making it a platform for multiomics cardiovascular studies.
- Published
- 2021
- Full Text
- View/download PDF